Cargando…

Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia

BACKGROUNDS: Chimeric antigen receptor (CAR)-T cell therapy has achieved unprecedented success in treating hematopoietic malignancies. However, this cell therapy is hampered in treating acute myeloid leukemia (AML) due to lack of ideal cell surface targets that only express on AML blasts and leukemi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Gongqiang, Guo, Shanshan, Luo, Qian, Wang, Xiaoxia, Deng, Wenhai, Ouyang, Guifang, Pu, Jeffrey J., Lei, Wen, Qian, Wenbin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950117/ https://www.ncbi.nlm.nih.gov/pubmed/36845088 http://dx.doi.org/10.3389/fimmu.2023.1093750

Ejemplares similares

CD70‐targeting CAR‐T cells have potential activity against CD19‐negative B‐cell Lymphoma
por: Deng, Wenhai, et al.
Publicado: (2021)

Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia
por: Cheng, Jiali, et al.
Publicado: (2023)

Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances
por: Liu, Jile, et al.
Publicado: (2023)

Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature
por: Zhao, Aiqi, et al.
Publicado: (2023)

Demethylating therapy increases cytotoxicity of CD44v6 CAR-T cells against acute myeloid leukemia
por: Tang, Ling, et al.
Publicado: (2023)

Engineering tandem CD33xCD146 CAR CIK (cytokine-induced killer) cells to target the acute myeloid leukemia niche
por: Alberti, Gaia, et al.
Publicado: (2023)

Sustained Remission of Relapsed or Refractory Mantle Cell Lymphoma After 4-1BB-Based CD19-Directed CAR-T Therapy
por: Yang, Chunmei, et al.
Publicado: (2020)

Case report: CD38-directed CAR-T cell therapy: A novel immunotherapy targeting CD38- positive blasts overcomes TKI and chemotherapy resistance of myeloid chronic myeloid leukemia in blastic phase
por: Cui, Qingya, et al.
Publicado: (2022)

Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells
por: Feng, Jia, et al.
Publicado: (2022)

CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report
por: Sun, Yao, et al.
Publicado: (2021)

Preclinical and clinical studies of CAR-NK-cell therapies for malignancies
por: Li, Hongwen, et al.
Publicado: (2022)

Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia
por: Calviño, Cristina, et al.
Publicado: (2023)

Engineering Cytoplasmic Signaling of CD28ζ CARs for Improved Therapeutic Functions
por: Meng, Xianhui, et al.
Publicado: (2020)

CAR T Cells Targeting Membrane-Bound Hsp70 on Tumor Cells Mimic Hsp70-Primed NK Cells
por: Bashiri Dezfouli, Ali, et al.
Publicado: (2022)

Repolarization of Tumor-Infiltrating Myeloid Cells for Augmentation of CAR T Cell Therapies
por: Luo, Weichuan, et al.
Publicado: (2022)

Preclinical Targeting of Human Acute Myeloid Leukemia Using CD4-specific Chimeric Antigen Receptor (CAR) T Cells and NK Cells
por: Salman, Huda, et al.
Publicado: (2019)

CD26(low)PD-1(+) CD8 T cells are terminally exhausted and associated with leukemia progression in acute myeloid leukemia
por: Zhou, Huarong, et al.
Publicado: (2023)

Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia
por: Rozenbaum, Meir, et al.
Publicado: (2020)

CAR T-Cell Therapy: Is CD28-CAR Heterodimerization Its Achilles’ Heel?
por: Ferreira, Leonardo M. R., et al.
Publicado: (2021)

89723 CD105-targeted CAR T cells for the treatment of acute myeloid leukemia
por: Lontos, Konstantinos, et al.
Publicado: (2021)

Clinical and preclinical characterization of CD99 isoforms in acute myeloid leukemia
por: Vaikari, Vijaya Pooja, et al.
Publicado: (2020)

A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells
por: Fergusson, Nathan J., et al.
Publicado: (2023)

Loss of CD28 expression associates with severe T-cell exhaustion in acute myeloid leukemia
por: Huang, Yueting, et al.
Publicado: (2023)

Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
por: Xu, Xinjie, et al.
Publicado: (2019)

Multiple CAR-T cell therapy for acute B-cell lymphoblastic leukemia after hematopoietic stem cell transplantation: A case report
por: Deng, Lei, et al.
Publicado: (2022)

NKT-Like (CD3+CD56+) Cells in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors
por: Almeida, Jani-Sofia, et al.
Publicado: (2019)

Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells
por: You, Liangshun, et al.
Publicado: (2020)

Case Report: CD19 and CD20 monoclonal antibodies with sequential chemotherapy for refractory acute B-lymphocytic leukemia in children
por: Li, Jia-Nan, et al.
Publicado: (2023)

Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia
por: Albinger, Nawid, et al.
Publicado: (2022)

One Stone, Two Birds: N6-Methyladenosine RNA Modification in Leukemia Stem Cells and the Tumor Immune Microenvironment in Acute Myeloid Leukemia
por: Ouyang, Xianfeng, et al.
Publicado: (2022)

The potential role of the thymus in immunotherapies for acute myeloid leukemia
por: Hino, Christopher, et al.
Publicado: (2023)

Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients
por: Qu, Changju, et al.
Publicado: (2022)

Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL
por: Aparicio-Pérez, Clara, et al.
Publicado: (2023)

CD70 CAR T cells in AML: Form follows function
por: Mirazee, Justin, et al.
Publicado: (2022)

Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia
por: Sugita, Mayumi, et al.
Publicado: (2022)

The cytokine network in acute myeloid leukemia
por: Luciano, Michela, et al.
Publicado: (2022)

CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumors
por: Dragon, Anna Christina, et al.
Publicado: (2023)

Preclinical models and evaluation criteria of prostatitis
por: He, Hailan, et al.
Publicado: (2023)

Association Analyses of TP53 Mutation With Prognosis, Tumor Mutational Burden, and Immunological Features in Acute Myeloid Leukemia
por: Wen, Xiang-mei, et al.
Publicado: (2021)

Acute myeloid leukemia therapeutics: CARs in the driver’s seat
por: Mardiros, Armen, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_kqt232ses13nivoivckrojc9le